search
Back to results

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Primary Purpose

Metastatic Pancreatic Ductal Adenocarcinoma

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Botensilimab
Gemcitabine
Nab-paclitaxel
Sponsored by
Agenus Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metastatic Pancreatic Ductal Adenocarcinoma focused on measuring BOT, 1181, Immunotherapy, Pancreas, Gemcitabine, Nab-paclitaxel

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Histologically confirmed diagnosis of pancreatic ductal adenocarcinoma. Must have had disease progression on any version of FOLFIRINOX for metastatic disease. Eastern Cooperative Oncology Group performance status of 0 or 1. Life expectancy of at least 3 months. Measurable disease on baseline imaging per RECIST 1.1 criteria. < Grade 2 pre-existing peripheral neuropathy per National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0. Acceptable coagulation status as indicated by an international normalized ratio ≤ 1.5x institutional ULN, except participants on anticoagulation who can be included at the discretion of the investigator. Adequate organ function. Women of childbearing potential must have a negative urine or serum pregnancy test at screening (within 72 hours of first dose of study drugs). Male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study. Exclusion Criteria: Received more than one prior regimen (that is, FOLFIRINOX) for their metastatic disease. History of central nervous system metastasis. Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study drugs (that is, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years prior to first dose of study drugs and the participant has no evidence of disease). Participants with history of prior early-stage basal/squamous cell skin cancer or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible. Uncontrolled intercurrent illness, including but not limited to clinically significant (that is, active) cardiovascular disease. Active, uncontrolled infections, requiring systemic intravenous anti-infective treatment within 2 weeks prior to first dose of study drugs. Major surgery within 4 weeks prior to signing of informed consent form (ICF). Prior treatment with an immune checkpoint inhibitor. Refractory ascites. Partial or complete bowel obstruction within the last 3 months prior to signing ICF, signs/symptoms of bowel obstruction, or known radiologic evidence of impending obstruction. Clinically significant gastrointestinal disorders. Treatment with one of the following classes of drugs within the delineated time window prior to first dose of study drugs: Cytotoxic agent within 3 weeks. Monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or investigational drug, within 4 weeks, or 5 half-lives, whichever is shorter. Small molecule/tyrosine kinase inhibitors within 14 days. Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to first dose of study drugs. SARS-CoV-2 vaccine < 7 days prior to first dose of study drugs. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients. Symptomatic interstitial lung disease (ILD), history of ILD or any lung disease which may interfere with detection and management of new immune-related pulmonary toxicity. History of allogeneic organ transplant. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study. Participants with a condition requiring systemic treatment with either corticosteroids (> 10 milligrams [mg] daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days prior to first dose of study drugs. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent), are permitted in the absence of active autoimmune disease. Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years prior to first dose of study drugs (that is, with use of disease-modifying agents or immunosuppressive drugs). Pregnant or breastfeeding participants. Uncontrolled infection with human immunodeficiency virus. Known to be positive for hepatitis B (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Known active hepatitis C as determined by positive serology and confirmed by polymerase chain reaction. Dependence on total parenteral nutrition. Participants with concurrent diarrhea > grade 1 at time of randomization despite optimal treatment with standard of care pancreatic enzymes. Known active or latent tuberculosis (testing at screening not required). Any condition in the opinion of the principal investigator that might interfere with the participant's participation in the study or in the evaluation of the study results. Unwillingness or inability to comply with procedures required in this protocol.

Sites / Locations

  • HonorHealthRecruiting
  • Providence St. Jude Medical Center - Crosson Cancer Institute
  • USC Norris Comprehensive Cancer CenterRecruiting
  • UCLA Health - Santa Monica Cancer Care
  • Medical Oncology Hematology Consultants (MOHC) - Helen F. Graham Cancer Center
  • Georgetown Lombardi Comprehensive Cancer Center
  • Florida Cancer Specialist South
  • Cancer Care Centers of Brevard
  • Florida Cancer Specialist North
  • Illinois Cancer Specialists
  • The Center for Cancer and Blood Disorders
  • Maryland Oncology Hematology
  • Beth Israel Deaconess Medical Center
  • Rogel Cancer Center, University of Michigan MedicineRecruiting
  • Minnesota Oncology
  • Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II*
  • John Theurer Cancer Center at HackensackRecruiting
  • Atlantic Health Systems, MorristownRecruiting
  • Overlook Medical Center
  • Columbia University Herbert Irving Comprehensive Cancer Center
  • Weill Cornell Medicine Sandra and Edward Meyer Cancer CenterRecruiting
  • Icahn School of Medicine at Mount Sinai Tisch Cancer InstituteRecruiting
  • Oncology Hematology Care - Eastgate
  • LifespanRecruiting
  • Sarah Cannon Research Institute at Tennessee OncologyRecruiting
  • Vanderbilt-Ingram Cancer Center
  • Texas Oncology
  • Baylor Charles A. Sammons Cancer Center
  • TxO - Denison Cancer Center
  • The Center for Cancer & Blood Disorders: Fort WorthRecruiting
  • Northeast Texas Cancer & Research Institute
  • Virginia Cancer SpecialistsRecruiting
  • Virginia Oncology Associates - Brock Cancer Center
  • Shenandoah Oncology
  • Swedish Cancer InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Part 1: Combination (Safety Lead-in Phase)

Part 2: Combination

Part 2: Standard of Care

Arm Description

Participants will receive botensilimab in combination with standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).

Participants will receive botensilimab in combination standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).

Participants will receive standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).

Outcomes

Primary Outcome Measures

Progression-free Survival
Progression-free survival will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression, assessed by investigators per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), or death, whichever occurs first.

Secondary Outcome Measures

Number Of Participants With Treatment-emergent Adverse Events
Overall Survival
Overall survival will be defined as the time from the date of randomization to the date of death due to any cause.
Complete Response
Complete response will be defined by RECIST 1.1 criteria and carbohydrate antigen 19-9 down to normal limits (from at least > 2x upper limit of normal [ULN]). Cancer antigen 125 or carcinoembryonic antigen will be evaluated for participants who are not expressors of carbohydrate antigen 19-9.
Overall Response Rate
Overall response rate will be defined as the proportion of participants whose best overall response is complete response or partial response per RECIST v1.1.
Duration Of Response
Duration of response will be defined as the time from the first determination of an objective response per RECIST v1.1, until the first documentation of progression or death, whichever occurs first.
Change From Baseline In Carbohydrate Antigen 19-9
Change in carbohydrate antigen 19-9 will be evaluated until progressive disease, death, date of last tumor assessment, or start of new anti-cancer therapy. Cancer antigen 125 or carcinoembryonic antigen will be evaluated for participants who are not expressors of carbohydrate antigen 19-9.
Rates Of Normalization Of Carbohydrate Antigen 19-9
Carbohydrate antigen 19-9 normalization will be defined as a value of carbohydrate antigen 19-9 down to normal limits (from at least > 2x ULN). Cancer antigen 125 or carcinoembryonic antigen will be evaluated for participants who are not expressors of carbohydrate antigen 19-9.

Full Information

First Posted
November 18, 2022
Last Updated
September 18, 2023
Sponsor
Agenus Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05630183
Brief Title
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Official Title
A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 27, 2023 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Agenus Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.
Detailed Description
This will be a prospective, multicenter, clinical trial of botensilimab in combination with nab-paclitaxel + gemcitabine or nab-paclitaxel + gemcitabine alone. The trial will be conducted in 2 parts. Part 1 will be a safety lead-in to establish the safety and dose of botensilimab for Part 2. Part 2 will be a randomized, open-label assessment of botensilimab (at the dose level determined in Part 1).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Pancreatic Ductal Adenocarcinoma
Keywords
BOT, 1181, Immunotherapy, Pancreas, Gemcitabine, Nab-paclitaxel

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
78 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part 1: Combination (Safety Lead-in Phase)
Arm Type
Experimental
Arm Description
Participants will receive botensilimab in combination with standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
Arm Title
Part 2: Combination
Arm Type
Experimental
Arm Description
Participants will receive botensilimab in combination standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
Arm Title
Part 2: Standard of Care
Arm Type
Active Comparator
Arm Description
Participants will receive standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
Intervention Type
Drug
Intervention Name(s)
Botensilimab
Other Intervention Name(s)
AGEN1181
Intervention Description
A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
Intervention Type
Drug
Intervention Name(s)
Gemcitabine
Intervention Description
Standard-of-care chemotherapy administered intravenously.
Intervention Type
Drug
Intervention Name(s)
Nab-paclitaxel
Intervention Description
Standard-of-care chemotherapy administered intravenously.
Primary Outcome Measure Information:
Title
Progression-free Survival
Description
Progression-free survival will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression, assessed by investigators per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), or death, whichever occurs first.
Time Frame
Up to 2 years
Secondary Outcome Measure Information:
Title
Number Of Participants With Treatment-emergent Adverse Events
Time Frame
First study dose through up 1 year
Title
Overall Survival
Description
Overall survival will be defined as the time from the date of randomization to the date of death due to any cause.
Time Frame
Up to 2 years
Title
Complete Response
Description
Complete response will be defined by RECIST 1.1 criteria and carbohydrate antigen 19-9 down to normal limits (from at least > 2x upper limit of normal [ULN]). Cancer antigen 125 or carcinoembryonic antigen will be evaluated for participants who are not expressors of carbohydrate antigen 19-9.
Time Frame
Up to 2 years
Title
Overall Response Rate
Description
Overall response rate will be defined as the proportion of participants whose best overall response is complete response or partial response per RECIST v1.1.
Time Frame
Up to 2 years
Title
Duration Of Response
Description
Duration of response will be defined as the time from the first determination of an objective response per RECIST v1.1, until the first documentation of progression or death, whichever occurs first.
Time Frame
Up to 2 years
Title
Change From Baseline In Carbohydrate Antigen 19-9
Description
Change in carbohydrate antigen 19-9 will be evaluated until progressive disease, death, date of last tumor assessment, or start of new anti-cancer therapy. Cancer antigen 125 or carcinoembryonic antigen will be evaluated for participants who are not expressors of carbohydrate antigen 19-9.
Time Frame
Baseline, 2 years
Title
Rates Of Normalization Of Carbohydrate Antigen 19-9
Description
Carbohydrate antigen 19-9 normalization will be defined as a value of carbohydrate antigen 19-9 down to normal limits (from at least > 2x ULN). Cancer antigen 125 or carcinoembryonic antigen will be evaluated for participants who are not expressors of carbohydrate antigen 19-9.
Time Frame
Up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed diagnosis of pancreatic ductal adenocarcinoma. Must have had disease progression on any version of FOLFIRINOX for metastatic disease. Eastern Cooperative Oncology Group performance status of 0 or 1. Life expectancy of at least 3 months. Measurable disease on baseline imaging per RECIST 1.1 criteria. < Grade 2 pre-existing peripheral neuropathy per National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0. Acceptable coagulation status as indicated by an international normalized ratio ≤ 1.5x institutional ULN, except participants on anticoagulation who can be included at the discretion of the investigator. Adequate organ function. Women of childbearing potential must have a negative urine or serum pregnancy test at screening (within 72 hours of first dose of study drugs). Male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study. Exclusion Criteria: Received more than one prior regimen (that is, FOLFIRINOX) for their metastatic disease. History of central nervous system metastasis. Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study drugs (that is, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years prior to first dose of study drugs and the participant has no evidence of disease). Participants with history of prior early-stage basal/squamous cell skin cancer or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible. Uncontrolled intercurrent illness, including but not limited to clinically significant (that is, active) cardiovascular disease. Active, uncontrolled infections, requiring systemic intravenous anti-infective treatment within 2 weeks prior to first dose of study drugs. Major surgery within 4 weeks prior to signing of informed consent form (ICF). Prior treatment with an immune checkpoint inhibitor. Refractory ascites. Partial or complete bowel obstruction within the last 3 months prior to signing ICF, signs/symptoms of bowel obstruction, or known radiologic evidence of impending obstruction. Clinically significant gastrointestinal disorders. Treatment with one of the following classes of drugs within the delineated time window prior to first dose of study drugs: Cytotoxic agent within 3 weeks. Monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or investigational drug, within 4 weeks, or 5 half-lives, whichever is shorter. Small molecule/tyrosine kinase inhibitors within 14 days. Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to first dose of study drugs. SARS-CoV-2 vaccine < 7 days prior to first dose of study drugs. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients. Symptomatic interstitial lung disease (ILD), history of ILD or any lung disease which may interfere with detection and management of new immune-related pulmonary toxicity. History of allogeneic organ transplant. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study. Participants with a condition requiring systemic treatment with either corticosteroids (> 10 milligrams [mg] daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days prior to first dose of study drugs. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent), are permitted in the absence of active autoimmune disease. Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years prior to first dose of study drugs (that is, with use of disease-modifying agents or immunosuppressive drugs). Pregnant or breastfeeding participants. Uncontrolled infection with human immunodeficiency virus. Known to be positive for hepatitis B (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Known active hepatitis C as determined by positive serology and confirmed by polymerase chain reaction. Dependence on total parenteral nutrition. Participants with concurrent diarrhea > grade 1 at time of randomization despite optimal treatment with standard of care pancreatic enzymes. Known active or latent tuberculosis (testing at screening not required). Any condition in the opinion of the principal investigator that might interfere with the participant's participation in the study or in the evaluation of the study results. Unwillingness or inability to comply with procedures required in this protocol.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Agenus, Inc. Clinical Trial Information
Phone
781-674-4265
Email
clinicaltrialinfo@Agenusbio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Agenus Inc.
Official's Role
Study Director
Facility Information:
Facility Name
HonorHealth
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erkut Borazanci
Facility Name
Providence St. Jude Medical Center - Crosson Cancer Institute
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
Individual Site Status
Withdrawn
Facility Name
USC Norris Comprehensive Cancer Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diana Hanna
Facility Name
UCLA Health - Santa Monica Cancer Care
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
J. Randolph Hecht
Facility Name
Medical Oncology Hematology Consultants (MOHC) - Helen F. Graham Cancer Center
City
Newark
State/Province
Delaware
ZIP/Postal Code
19713
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jamal Misleh
Facility Name
Georgetown Lombardi Comprehensive Cancer Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20057
Country
United States
Individual Site Status
Withdrawn
Facility Name
Florida Cancer Specialist South
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33901
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Syed Zafar
Facility Name
Cancer Care Centers of Brevard
City
Palm Bay
State/Province
Florida
ZIP/Postal Code
32909
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pavan Kancharla
Facility Name
Florida Cancer Specialist North
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
22705
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maen Hussein
Facility Name
Illinois Cancer Specialists
City
Arlington Heights
State/Province
Illinois
ZIP/Postal Code
60005
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Richard Siegel
Facility Name
The Center for Cancer and Blood Disorders
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20817
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Maryland Oncology Hematology
City
Columbia
State/Province
Maryland
ZIP/Postal Code
21044
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yousuf Gaffar
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Bullock
Facility Name
Rogel Cancer Center, University of Michigan Medicine
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Enzler
Facility Name
Minnesota Oncology
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55404
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Timothy Larson
Facility Name
Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II*
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89144
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brian Vicuna
Facility Name
John Theurer Cancer Center at Hackensack
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Gutierrez
Facility Name
Atlantic Health Systems, Morristown
City
Morristown
State/Province
New Jersey
ZIP/Postal Code
07960
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angela Alistar
Facility Name
Overlook Medical Center
City
Summit
State/Province
New Jersey
ZIP/Postal Code
07901
Country
United States
Individual Site Status
Withdrawn
Facility Name
Columbia University Herbert Irving Comprehensive Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Withdrawn
Facility Name
Weill Cornell Medicine Sandra and Edward Meyer Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pashtoon Kasi
Facility Name
Icahn School of Medicine at Mount Sinai Tisch Cancer Institute
City
New York
State/Province
New York
ZIP/Postal Code
10128
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Deirdre Cohen
Facility Name
Oncology Hematology Care - Eastgate
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45245
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mark Johns
Facility Name
Lifespan
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander Raufi
Facility Name
Sarah Cannon Research Institute at Tennessee Oncology
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Meredith Pelster
Facility Name
Vanderbilt-Ingram Cancer Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Individual Site Status
Withdrawn
Facility Name
Texas Oncology
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75010
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Enrique Perez
Facility Name
Baylor Charles A. Sammons Cancer Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75247
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Scott Paulson
Facility Name
TxO - Denison Cancer Center
City
Denison
State/Province
Texas
ZIP/Postal Code
75020
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amir Faridi
Facility Name
The Center for Cancer & Blood Disorders: Fort Worth
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henry Xiong
Facility Name
Northeast Texas Cancer & Research Institute
City
Tyler
State/Province
Texas
ZIP/Postal Code
75702
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Donald Richards
Facility Name
Virginia Cancer Specialists
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
M. Adham Salkeni
Facility Name
Virginia Oncology Associates - Brock Cancer Center
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yue Zhang
Facility Name
Shenandoah Oncology
City
Winchester
State/Province
Virginia
ZIP/Postal Code
22601
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William Houck
Facility Name
Swedish Cancer Institute
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philip Gold

12. IPD Sharing Statement

Learn more about this trial

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

We'll reach out to this number within 24 hrs